Erasca Advances ERAS-0015 Clinical Development Ahead of Schedule
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Should l Buy ERAS?
"We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule," said Jonathan Lim, Erasca's chairman, CEO, and co-founder. "The best-in-class potential of ERAS-0015 is striking, highlighted by robust responses in patients with KRAS G12X lung or pancreatic cancer, along with favorable safety and tolerability results primarily consisting of low-grade adverse events in our recently reported data. Notably, we believe ERAS-0015 has the potential to become a backbone of combination therapy based in part on the initial panitumumab combination data we shared last month. We continue to advance monotherapy expansion and combination dose escalation cohorts, with data from both anticipated in the first half of 2027."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.440
Low
2.00
Averages
5.50
High
11.00
Current: 10.440
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Under Investigation, Shares Plunge 48.3%
- Investigation Launched: The Schall Law Firm has announced an investigation into Erasca for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Patent Infringement Allegations: On April 28, 2026, Erasca received a letter from Revolution Medicines claiming that its ERAS-0015 infringes on Revolution's patents and involves allegations of trade secret misappropriation, increasing legal risks for the company.
- Stock Price Plunge: Following this news, Erasca's shares fell by 48.3% on the same day, indicating extreme market concern regarding the company's future prospects, which may lead to a decline in investor confidence.
- Investor Rights Advocacy: The Schall Law Firm is urging affected shareholders to participate in the lawsuit, emphasizing its expertise in securities class actions and shareholder rights litigation, aiming to provide legal support for investors.
See More
Erasca Under Investigation for Securities Law Violations
- Stock Price Plunge: Erasca, Inc. shares fell over 45% in premarket trading on April 28, 2026, after receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, leading to a significant loss of investor confidence.
- Legal Investigation Initiated: Block & Leviton is investigating whether Erasca violated securities laws and may file a lawsuit to recover losses on behalf of investors, a move that could further impact the company's reputation and shareholder trust.
- Investor Remediation Options: All investors who have lost money in Erasca are encouraged to contact Block & Leviton to learn how to pursue legal recovery, potentially prompting more investors to take action and affecting the company's future shareholder structure.
- Whistleblower Reward Program: Block & Leviton is urging whistleblowers with non-public information to assist in the investigation, with rewards of up to 30% of any successful recovery, a policy that may attract more insiders to participate and increase the legal risks faced by the company.
See More
Block & Leviton Investigates Erasca for Potential Securities Violations
- Stock Price Plunge: Erasca, Inc. shares fell over 45% in premarket trading on April 28, 2026, after the company disclosed a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, significantly undermining investor confidence.
- Legal Investigation Initiated: Block & Leviton is investigating whether Erasca committed securities law violations and plans to file an action to recover losses on behalf of investors, indicating potential legal risks that could affect the company's future financing and operations.
- Investor Rights Protection: All shareholders who have lost money in Erasca are encouraged to contact Block & Leviton to learn how to recover their losses through legal means, which may attract more affected investors and increase the company's legal liabilities.
- Whistleblower Reward Program: Block & Leviton is urging whistleblowers with non-public information to assist in the investigation, with rewards of up to 30% of any successful recovery, a policy that could encourage more insiders to come forward and increase legal pressure on Erasca.
See More
Erasca Stock Surges 16.9% Amid Optimism for Cancer Treatment
- Stock Rebound: Erasca Inc. shares surged 16.90% to close at $10.65 after a four-day losing streak, indicating investor bargain-hunting following a steep decline, reflecting renewed optimism surrounding its cancer treatment candidate.
- Clinical Trial Incident: Despite the confirmation of a 66-year-old male patient's death during the trial due to withdrawal of supportive care, Erasca deemed this a 'rare event' and continues to advance the development of ERAS-0015, showcasing confidence in its therapeutic potential.
- Efficacy Data: The company reported that ERAS-0015 demonstrated favorable response rates in its Phase 1 trial, with over half of lung cancer patients experiencing tumor shrinkage and around 50% of pancreatic cancer patients showing similar results, highlighting its competitive edge in the market.
- Future Development Potential: CEO Jonathan Lim noted that ERAS-0015 may be combined with standard-of-care panitumumab, positioning it as a potential backbone therapy for future combination regimens, indicating strategic growth opportunities in cancer treatment.
See More
Erasca Shares Plunge 48% Following Patient Death
- Significant Stock Drop: Erasca's shares plummeted 48% to $9.90 on Tuesday after the company reported a patient death related to its ERAS-0015 trial, intensifying investor scrutiny over safety data.
- Surge in Trading Volume: The trading volume reached 51 million shares, approximately 709% above the three-month average, indicating a strong market reaction and heightened volatility among investors.
- Pending Clinical Trial Results: While ERAS-0015 has shown outcomes exceeding benchmarks in lung and pancreatic cancer patients, the market must await full trial results to determine if pneumonitis becomes a common issue, impacting future treatment protocols.
- Strong Long-Term Performance: Despite the sharp decline today, Erasca's stock has risen sevenfold over the past year, reflecting market confidence in its long-term potential, suggesting that today's drop may be a cautious response to prior gains.
See More
Tech Stocks Decline Following OpenAI Misses
- Oracle Stock Drop: Oracle's shares fell over 3% after OpenAI missed its user and revenue targets, raising concerns about the sustainability of AI spending and impacting its $300 billion five-year partnership with OpenAI.
- Chip Stocks Decline: Following the OpenAI news, Nvidia and AMD saw declines of over 3% and 4%, respectively, while Arm Holdings plummeted more than 8%, indicating a waning market confidence in AI infrastructure.
- Centene Guidance Raise: Centene's shares surged 12% after it raised its full-year adjusted EPS guidance to over $3.40, surpassing the market consensus of $3.02, reflecting strong performance in the health insurance sector.
- Erasca Stock Plunge: Erasca's stock cratered nearly 50% after reporting a patient death in an early-stage trial, despite analysts viewing the incident as isolated, highlighting investor sensitivity to risks in the biotech sector.
See More
Erasca Under Investigation, Shares Plunge 48.3%
- Investigation Launched: The Schall Law Firm has announced an investigation into Erasca for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Patent Infringement Allegations: On April 28, 2026, Erasca received a letter from Revolution Medicines claiming that its ERAS-0015 infringes on Revolution's patents and involves allegations of trade secret misappropriation, increasing legal risks for the company.
- Stock Price Plunge: Following this news, Erasca's shares fell by 48.3% on the same day, indicating extreme market concern regarding the company's future prospects, which may lead to a decline in investor confidence.
- Investor Rights Advocacy: The Schall Law Firm is urging affected shareholders to participate in the lawsuit, emphasizing its expertise in securities class actions and shareholder rights litigation, aiming to provide legal support for investors.
See More
Erasca Under Investigation for Securities Law Violations
- Stock Price Plunge: Erasca, Inc. shares fell over 45% in premarket trading on April 28, 2026, after receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, leading to a significant loss of investor confidence.
- Legal Investigation Initiated: Block & Leviton is investigating whether Erasca violated securities laws and may file a lawsuit to recover losses on behalf of investors, a move that could further impact the company's reputation and shareholder trust.
- Investor Remediation Options: All investors who have lost money in Erasca are encouraged to contact Block & Leviton to learn how to pursue legal recovery, potentially prompting more investors to take action and affecting the company's future shareholder structure.
- Whistleblower Reward Program: Block & Leviton is urging whistleblowers with non-public information to assist in the investigation, with rewards of up to 30% of any successful recovery, a policy that may attract more insiders to participate and increase the legal risks faced by the company.
See More
Block & Leviton Investigates Erasca for Potential Securities Violations
- Stock Price Plunge: Erasca, Inc. shares fell over 45% in premarket trading on April 28, 2026, after the company disclosed a letter from Revolution Medicines alleging that its ERAS-0015 infringes a patent and involves trade secret misappropriation, significantly undermining investor confidence.
- Legal Investigation Initiated: Block & Leviton is investigating whether Erasca committed securities law violations and plans to file an action to recover losses on behalf of investors, indicating potential legal risks that could affect the company's future financing and operations.
- Investor Rights Protection: All shareholders who have lost money in Erasca are encouraged to contact Block & Leviton to learn how to recover their losses through legal means, which may attract more affected investors and increase the company's legal liabilities.
- Whistleblower Reward Program: Block & Leviton is urging whistleblowers with non-public information to assist in the investigation, with rewards of up to 30% of any successful recovery, a policy that could encourage more insiders to come forward and increase legal pressure on Erasca.
See More
Erasca Stock Surges 16.9% Amid Optimism for Cancer Treatment
- Stock Rebound: Erasca Inc. shares surged 16.90% to close at $10.65 after a four-day losing streak, indicating investor bargain-hunting following a steep decline, reflecting renewed optimism surrounding its cancer treatment candidate.
- Clinical Trial Incident: Despite the confirmation of a 66-year-old male patient's death during the trial due to withdrawal of supportive care, Erasca deemed this a 'rare event' and continues to advance the development of ERAS-0015, showcasing confidence in its therapeutic potential.
- Efficacy Data: The company reported that ERAS-0015 demonstrated favorable response rates in its Phase 1 trial, with over half of lung cancer patients experiencing tumor shrinkage and around 50% of pancreatic cancer patients showing similar results, highlighting its competitive edge in the market.
- Future Development Potential: CEO Jonathan Lim noted that ERAS-0015 may be combined with standard-of-care panitumumab, positioning it as a potential backbone therapy for future combination regimens, indicating strategic growth opportunities in cancer treatment.
See More
Erasca Shares Plunge 48% Following Patient Death
- Significant Stock Drop: Erasca's shares plummeted 48% to $9.90 on Tuesday after the company reported a patient death related to its ERAS-0015 trial, intensifying investor scrutiny over safety data.
- Surge in Trading Volume: The trading volume reached 51 million shares, approximately 709% above the three-month average, indicating a strong market reaction and heightened volatility among investors.
- Pending Clinical Trial Results: While ERAS-0015 has shown outcomes exceeding benchmarks in lung and pancreatic cancer patients, the market must await full trial results to determine if pneumonitis becomes a common issue, impacting future treatment protocols.
- Strong Long-Term Performance: Despite the sharp decline today, Erasca's stock has risen sevenfold over the past year, reflecting market confidence in its long-term potential, suggesting that today's drop may be a cautious response to prior gains.
See More
Tech Stocks Decline Following OpenAI Misses
- Oracle Stock Drop: Oracle's shares fell over 3% after OpenAI missed its user and revenue targets, raising concerns about the sustainability of AI spending and impacting its $300 billion five-year partnership with OpenAI.
- Chip Stocks Decline: Following the OpenAI news, Nvidia and AMD saw declines of over 3% and 4%, respectively, while Arm Holdings plummeted more than 8%, indicating a waning market confidence in AI infrastructure.
- Centene Guidance Raise: Centene's shares surged 12% after it raised its full-year adjusted EPS guidance to over $3.40, surpassing the market consensus of $3.02, reflecting strong performance in the health insurance sector.
- Erasca Stock Plunge: Erasca's stock cratered nearly 50% after reporting a patient death in an early-stage trial, despite analysts viewing the incident as isolated, highlighting investor sensitivity to risks in the biotech sector.
See More
